08:00 , Dec 24, 2012 |  BC Week In Review  |  Company News

Sinclair IS Pharma, Biocodex sales and marketing update

Sinclair granted Biocodex rights to commercialize Sinclair's dermatology portfolio in Russia, Turkey and the Benelux countries for 10 years. Biocodex will be responsible for product importation, distribution and promotion of the portfolio, which includes Kelo-cote,...
07:00 , Sep 17, 2012 |  BC Week In Review  |  Company News

Quintiles, Sinclair IS Pharma sales and marketing update

Quintiles Transnational Corp., Research Triangle Park, N.C.   Sinclair IS Pharma plc (LSE:SPH), London, U.K.   Business: Dermatology   Sinclair granted Quintiles rights to commercialize Sinclair's portfolio of dermo-cosmetic products and medical devices in Mexico for 10 years....
07:00 , Sep 26, 2011 |  BC Week In Review  |  Company News

Invida, Sinclair IS Pharma Inc. sales and marketing update

Invida launched Atopiclair non-steroidal cream in Hong Kong, Malaysia, Singapore and India to treat atopic dermatitis (eczema). Invida also launched Papulex nicotinamide 4% in Taiwan, India and Hong Kong to treat mild to moderate...
07:00 , Sep 20, 2010 |  BC Week In Review  |  Clinical News

Atopiclair regulatory update

Sinclair said Atopiclair cream was granted French reimbursement approval to treat atopic dermatitis. The company expects to launch the non-steroidal cream in France on Sept. 23. Sinclair Pharma plc (LSE:SPH), Godalming, U.K.   Product: Atopiclair...
08:00 , Jan 5, 2009 |  BC Week In Review  |  Company News

Sinclair, York Pharma sales and marketing update

The companies will co-promote certain of each other's dermatology products, including Sinclair's Atopiclair non-steroidal cream for atopic dermatitis and York's Zindaclin clindamycin to treat acne in the U.K. York gained Zindaclin through its...
07:00 , Jul 7, 2008 |  BC Week In Review  |  Company News

Sinclair, Wockhardt sales and marketing update

Sinclair granted Wockhardt exclusive Indian rights to market Atopiclair, a non-steroidal cream for atopic dermatitis; Aloclair, an oral rinse to treat mouth ulcers; Papulex nicotinamide 4% to treat acne; and Decapinol, an...
07:00 , Oct 1, 2007 |  BC Week In Review  |  Company News

Sinclair, Dr. Reddy's sales and marketing update

Sinclair Pharma plc (LSE:SPH), Godalming, U.K.  Dr. Reddy's Laboratories Ltd. (RDY), Hyderabad, India  Business: Dermatology  SPH launched Atopiclair non-steroidal cream for atopic dermatitis and Xclair hydrolipidic cream for radiation dermatitis in the U.K. SPH's Ashbourne Pharmaceuticals unit and...
07:00 , Sep 17, 2007 |  BC Week In Review  |  Clinical News

Atopiclair regulatory update

SPH received Australian marketing approval for Atopiclair as a class IIa medical device to treat atopic dermatitis (eczema). Intendis GmbH, a unit of Bayer AG (FSE:BAY; BAY, Leverkusen, Germany), co-markets the non-steroidal cream as...
07:00 , Jun 11, 2007 |  BC Week In Review  |  Company News

Sinclair, Bayer sales and marketing update

BAY's Intendis GmbH unit launched SHP's Zarzenda cream to treat atopic dermatitis and contact dermatitis in Austria, Italy, France, Germany and Spain. The companies already co-market the non-steroidal cream as Atopiclair in France and...
08:00 , Dec 4, 2006 |  BC Week In Review  |  Clinical News

Atopiclair dermatology data

In a double-blind trial in 40 patients aged 2-17, Atopiclair met the primary and secondary endpoints. On the primary endpoint, 80% of patients taking Atopiclair were considered treatment successes after 22 days vs. 26% of...